A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

Solid Tumor Clinical Trial

Official title:

A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02730481
• Other study ID #: KX-ORAX-004
• Status: Completed
• Phase: Phase 1
• Start date: March 2016
• Est. completion date: May 2021

Study information

• Verified date: September 2021
• Source: Athenex, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: May 2021
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. =18 years of age

3. Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

4. Measurable disease as per RECIST v1.1 criteria

5. Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain: ANC =1500 cells/mm3, Platelet count =100 x 109/L, Hemoglobin =9 g/dL

6. Adequate liver function as demonstrated by:Total bilirubin of =1.5 mg/dL or =2.0 mg/dL for subjects with liver metastasis, Alanine aminotransferase =3 x upper limit of normal (ULN) or =5 x ULN if liver metastasis is present, Alkaline phosphatase =3 x ULN or =5 x ULN if bone or liver metastasis is present

7. Adequate renal function as demonstrated by serum creatinine =1.5 x ULN or creatinine clearance calculation =60 mL/min as calculated by the Cockcroft and Gault formula

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

9. Life expectancy of at least 3 months

10. Women must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.

11. Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.

Exclusion Criteria:

1. Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)

2. Received IPs within 30 days or 5 half lives of the first study dosing day

3. Are currently receiving other medications or radiation intended for the treatment of their malignancy

4. Women of childbearing potential who are pregnant or breastfeeding

5. Currently taking a concomitant medication

6. Require therapeutic use of anticoagulation medications

7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements

8. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption

9. History of hypersensitivity to paclitaxel, not attributed to a hypersensitivity type reaction to Cremophor

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• Oraxol
Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Cancer Therapy &Research Center @ UTHSCSA	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Athenex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of Oraxol	The highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment	20 weeks
Secondary	Evaluate tumor response	RECIST v1.1 criteria defined as complete response, partial response, stable disease or progressive disease	At baseline and every 8 weeks through study completion, approximately 24 months
Secondary	Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment	Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment	4 weeks
Secondary	The amount of Oraxol in the blood stream	The measurement of Oraxol levels in the blood stream over time	3 weeks
Secondary	The recommended Phase 2 dose of paclitaxel as Oraxol	The totality of information from the number of participants that reach the MTD (outcome #1), the number of participants that experience abnormal laboratory values and/or adverse events that are related to treatment (outcome #3), and the amount of Oraxol in the blood stream in participants (outcome #4)	24 months